Joshua Kazam

Joshua is a co-founder and director of Kronos Bio. Josh is also a co-founder and director of Allogene Therapeutics. Inc. (ALLO) and is a co-founder and Partner of Two River, where he has served as partner since its inception in 2004. He is a co-founder and partner of Vida Ventures, LLC, a life science investment firm, and was a co-founder and director of Kite Pharma, Inc., where he served on the Board of Directors from inception until its acquisition by Gilead Sciences, Inc. in 2017. Joshua also serves as a director of several privately held companies including Hubble Contacts, ByHeart Inc, and Breakthrough Properties, LLC.

Joshua is a Member of the Wharton School’s Undergraduate Executive Board and serves on the Board of the Desert Flower Foundation. He received his B.S. in Economics from the Wharton School of the University of Pennsylvania.